COSA 2015* , ,
Presentations this author is a contributor to:
Clinical response, progression-free survival (PFS) and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) versus IPI monotherapy in CheckMate 069 study (#163)
3:25 PM
F Stephen Hodi
Best of the Best Posters - Epidemiology & Health services
Nivolumab (Nivo) monotherapy or in combination with ipilimumab (Ipi) for treatment of recurrent small cell lung cancer (SCLC) (#187)
3:00 PM
Emiliano Calvo
Posters1